Laryngeal Mask Airway versus Tracheal Tube for Endovascular Treatment

• Register: ANZCTR
• Last refreshed on: 11 June 2018
• Main ID: ACTRN12618000509268
• Date of registration: 09/04/2018
• Prospective Registration: No
• Primary sponsor: 29 May Diyanet Foundation Hospital
• Public title: Laryngeal Mask Airway versus Tracheal Tube for Endovascular Treatment
• Scientific title: Laryngeal Mask Airway versus Tracheal Tube for Endovascular Treatment of Unruptured Cerebral Aneurysms: A Randomized Trial Of Safety And Efficacy
• Date of first enrolment: 1/05/2010
• Target sample size: 40
• Recruitment status: Completed
• URL: http://www.anzctr.org.au/ACTRN12618000509268.aspx
• Study type: Interventional
• Study design: Randomised controlled trial Parallel

Health Condition(s) or Problem(s) studied

Unruptured cerebrovascular aneurysms

hypertension

Intervention(s)

Patients undergoing Endovascular treatment (EVT) for unruptured cerebrovascular aneurysms were randomized to secure the airway with a laryngeal mask airway (LMA, a supraglottic airway device which is frequently used to secure airway for general anesthesia, and also as an alternative to tracheal tube for difficult airway interventions) or tracheal tube (TT). LMA is placed after the induction of general anesthesia, and removed at the end of the procedure, which means after the surgery and/ or intervention is completed, anesthesia is discontinued and the patient is awaked, the same conditions for TT. Anesthesia was induced with propofol and fentanyl and maintained with remifentanil/propofol-based intravenous anesthesia. Rocuronium ( a nondepolarizing neuromuscular blocker, 0.6 mg/kg intravenously, after the induction of general anesthesia, additional doses were not given) was used in group TT to facilitate tracheal intubation. Hemodynamic parameters were measured before and after airway management and throughout the procedure. After the procedure, recovery times were measured. Respiratory events were recorded.